BerendSnijder Profile Banner
Berend Snijder Profile
Berend Snijder

@BerendSnijder

Followers
583
Following
424
Media
2
Statuses
103

systems biology, pharmacoscopy, biological networks, big data, amsterdammer

Joined April 2015
Don't wanna be here? Send us removal request.
@BerendSnijder
Berend Snijder
1 year
See you there!
@MRC_TIDU
MRC TIDU
1 year
IMMOX'25 - Genetic Variation and Barrier Immunity, Oxford, UK, March 17th - 19th 2025 FANTASTIC SPEAKER LINEUP for a great meeting. Browse the website for full details - https://t.co/9MlFf1pIyz #IMMOX25 #BarrierImmunity #MucosalImmunology #Immunity #Immunology #tcell
0
0
2
@NatureMedicine
Nature Medicine
1 year
A single-cell ex vivo screening of repurposable drugs in #glioblastoma coupled with machine learning show that anti-tumour neuroactive drugs converge on the AP1-BTG pathway and identify the antidepressant vortioxetine as a potential therapeutic agent. https://t.co/JQEOa5iz8f
nature.com
Nature Medicine - A single-cell ex vivo screening of repurposable drugs in glioblastoma and machine learning of drug–target networks show that anti-tumor neuroactive drugs converge on the...
0
12
45
@aipulserx
DailyHealthcareAI
1 year
Molecular and functional landscape of malignant serous effusions for precision oncology @NatureMedicine @BerendSnijder Personalized treatment for patients with advanced solid tumors critically depends on the deep characterization of tumor cells from patient biopsies. Here, we
0
2
5
@NatureMedicine
Nature Medicine
1 year
A single-cell ex vivo screening of repurposable drugs in #glioblastoma coupled with machine learning show that anti-tumour neuroactive drugs converge on the AP1-BTG pathway and identify the antidepressant vortioxetine as a potential therapeutic agent. https://t.co/JQEOa5iz8f
nature.com
Nature Medicine - A single-cell ex vivo screening of repurposable drugs in glioblastoma and machine learning of drug–target networks show that anti-tumor neuroactive drugs converge on the...
1
32
105
@to123w
Tobias W.
1 year
I'm thrilled to announce that our latest study, led by the incredible @BerendSnijder and Sohyon Lee, has been published in @NatureMedicine. It has been an amazing journey and it paves the way for many future explorations https://t.co/9TTuI37liG
nature.com
Nature Medicine - A single-cell ex vivo screening of repurposable drugs in glioblastoma and machine learning of drug–target networks show that anti-tumor neuroactive drugs converge on the...
7
25
129
@tmprowell
Tatiana Prowell, MD
1 year
🧵 NEW 📣 Profiling of >100 approved drugs, mostly cancer drugs & other CNS-penetrant drugs incl antidepressants points to Ca2+-driven AP-1/BTG-pathway induction as a #glioblastoma vulnerability. Authors propose drug-repurposing trials + std chemo for #GBM. #OncTwitter #btsm
3
10
36
@ETH_en
ETH Zurich
1 year
Researchers at ETH Zurich have used a drug screening platform they developed to show that an #Antidepressant, currently on the market, kills #Tumour cells in the dreaded #Glioblastoma – at least in the cell-culture dish.
Tweet card summary image
ethz.ch
Researchers at ETH Zurich have used a drug screening platform they developed to show that an antidepressant, currently on the market, kills tumour cells in the dreaded glioblastoma – at least in the...
1
7
19
@BenHale95
Ben Hale
1 year
Looking forward to talking about #StripyTcells and our recent @ScienceMagazine publication with @thalexandrov, his team, and you (if you want)! The talk is public, so feel free to join: https://t.co/7F6GEPa4BN Big thanks to Theodore & co. for the invitation!
Tweet card summary image
embl-org.zoom.us
Zoom is the leader in modern enterprise cloud communications.
@thalexandrov
Theodore Alexandrov
1 year
As an external talk at @alexandrovteam meeting, on Tue 18th at 10:15am CEST, Ben Hale from the @BerendSnijder lab will present on their paper just out in Science https://t.co/zqz3WxqEtN The talk is open to public and everyone is welcome! 🔓 Link to join: https://t.co/JLuUyxJ9h9
0
3
10
@thalexandrov
Theodore Alexandrov
1 year
As an external talk at @alexandrovteam meeting, on Tue 18th at 10:15am CEST, Ben Hale from the @BerendSnijder lab will present on their paper just out in Science https://t.co/zqz3WxqEtN The talk is open to public and everyone is welcome! 🔓 Link to join: https://t.co/JLuUyxJ9h9
0
5
16
@BerendSnijder
Berend Snijder
1 year
Check out this Tweetorial for an easy summary of our recent paper
@snijderlab
Snijder Lab
1 year
#Tweetorial for our paper in @ScienceMagazine It's still largely unknown how naïve T cells decide to become either effector or memory T cells during viral infection. We show that these decisions are built into the cellular architecture of our T cells. 1/9 https://t.co/yOQgVaPgot
0
0
4
@Ri_Science
Royal Institution (now on Bluesky)
1 year
Find out more about the research from the paper's lead author @BenHale95 here ⬇️ https://t.co/7p2M5lNf0Q
0
2
7
@RamonPfaendler
Ramon Pfändler
1 year
Awesome #TikTorial & paper, happy to have been part of coercing you @BenHale95. 🤩
@snijderlab
Snijder Lab
1 year
And here is our first ever #TikTorial (?🤨) of our newest @ScienceMagazine paper! Tweetorial coming soon 🧵
0
1
11
@BerendSnijder
Berend Snijder
1 year
Very proud of this massive lab effort and beautiful outcome!
@snijderlab
Snijder Lab
1 year
Our big story on the importance of "stripy" T cells in antigen response, which started as a MSc Thesis 6 years ago, has finally made its way out in @ScienceMagazine! 🤩 Massive congrats to @BenHale95 & thanks to all collaborators particularly @LabOxenius & @blutspendesrk 🥰
5
1
19
@sarah_h_ross
Sarah Ross
1 year
Out now @ScienceMagazine: @BenHalePhD, @BerendSnijder & colleagues report that the internal architecture of T cells at the moment they are activated can influence their fate in response to antigen. 🔗 https://t.co/yMHMt6Ee0l
3
29
109
@Diana_Azzam_PhD
Diana Azzam
2 years
Thrilled to have participated today in an exciting session @AACR on the State of the Art in Functional Precision Medicine alongside leading experts @DrTonyLetai & @BerendSnijder @TheSFPM #AACR24 #SFPM #futureisfunctional
1
9
27
@DrTonyLetai
Anthony Letai MD PhD
2 years
Want to know what is coming in precision oncology? Join me, Berend Snijder and Diana Azzam to hear about the State of the Art in Functional Precision Medicine Friday afternoon at the AACR. https://t.co/yH20m5CRaT @TheSFPM @AACR
0
6
14